logo

This website uses cookies to ensure you get the best experience on our website.

Read through the Privacy Policy to understand better

 Go Back

Drug slows Alzheimer's but can it make a real difference?

By LAURAN NEERGAARD - Nov 29, 2022, 07:54 PM ET
Last Updated - Aug 02, 2024, 02:01 AM EDT
FDA_Building
The trial is important because it shows a drug that attacks a sticky protein called amyloid -- considered one of several culprits behind Alzheimer’s -- can delay disease progression, said Maria Carrillo, chief science officer for the Alzheimer’s Associatio

New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening

An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday -- but it remains unclear how much difference that might make in people’s lives. 

Japanese drugmaker Eisai and its U.S. partner Biogen had announced earlier this fall that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better Alzheimer’s treatments. 

Sponsored

Now the companies are providing full results of the study of nearly 1,800 people in the earliest stages of the mind-robbing disease. The data was presented at an Alzheimer’s meeting in San Francisco and published in The New England Journal of Medicine. U.S. regulators could approve the drug as soon as January. 

Every two weeks for 18 months, study participants received intravenous lecanemab or a dummy infusion. Researchers tracked them using an 18-point scale that measures cognitive and functional ability.  

By continuing to use this site, you agree to our terms and conditions
Sponsored
Sponsored
Sponsored
Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
    Phone: +1 (425) 414-0184
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
    Phone: +91 80 4902 2100
4.2 20250324